Want to see MCRB full AI Analyst Report?
Top Page
Seres Therapeutics
(NASDAQ:MCRB)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
▲(0.81% Upside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak financial performance—ongoing large losses, negative returns, and significant cash burn—alongside a clearly bearish price trend and negative momentum signals. Offsetting factors include positive corporate actions (cost/lease restructuring and near-term cash from the milestone amendment) and encouraging early SER-155 data, but these are not yet enough to overcome the current financial and technical weakness.
Positive Factors
Revenue rebound & high gross margin
Sustained top-line recovery and an ~82.6% gross margin indicate attractive unit economics for Seres’ microbiome therapeutics. Durable high gross margins provide structural leverage to scale commercial programs and absorb R&D spend, improving long-term path to profitability if revenue growth persists.
Negative Factors
Persistent negative cash flow
Material and sustained negative operating and free cash flow (~-$51.3M TTM) means Seres cannot self-fund development long-term. Ongoing burn forces reliance on milestone payments, asset sales, or external financing, raising dilution or covenant risk and constraining investment in multiple pipeline programs concurrently.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue rebound & high gross margin
Sustained top-line recovery and an ~82.6% gross margin indicate attractive unit economics for Seres’ microbiome therapeutics. Durable high gross margins provide structural leverage to scale commercial programs and absorb R&D spend, improving long-term path to profitability if revenue growth persists.
Read all positive factors
Seres Therapeutics (MCRB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.13M
Dividend YieldN/A
Average Volume (3M)127.06K
Price to Earnings (P/E)―
Beta (1Y)1.23
Revenue GrowthN/A
EPS Growth71.26%
CountryUS
Employees66
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.42
Shares Outstanding9,941,261
10 Day Avg. Volume150,346
30 Day Avg. Volume127,062
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)2.98
Price to Sales (P/S)167.07
P/FCF Ratio152.39
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$17.00Price Target Upside242.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.25
Revenue Forecast (FY)$12.50M
Seres Therapeutics Business Overview & Revenue Model
Company Description
Seres Therapeutics, Inc. is a pioneering microbiome therapeutics firm dedicated to engineering bacterial consortia that modulate host cells and tissues to combat various diseases. Their flagship therapeutic, SER-109, an oral microbiome treatment, ...
How the Company Makes Money
Seres Therapeutics makes money primarily through (1) product-related revenue from commercialization of its microbiome therapeutic for recurrent C. difficile infection (when and where it is marketed by the company and/or its partners, depending on ...
Seres Therapeutics Earnings Call Summary
Earnings Call Date:Nov 05, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Nov 11, 2026
Earnings Call Sentiment Positive
The call highlighted significant clinical progress and financial recovery, supported by external funding and strategic cost reductions. However, the dependency on securing further capital for future studies poses a notable challenge.Positive Updates
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Negative Updates
Dependence on Funding for Phase II Study
The commencement of SER-155 Phase II study is funding dependent, and the company is actively seeking partnerships or other capital sources.
Read all updates
Q3-2025 Updates
Positive
Negative
SER-155 Clinical Progress
SER-155 Phase Ib study showed a 77% relative risk reduction in bacterial bloodstream infections, decreased antibiotic exposure, and febrile neutropenia. The FDA provided constructive feedback, aligning on key study parameters for the Phase II protocol.
Read all positive updates
Company Guidance
During the Q3 2025 call, Seres Therapeutics highlighted significant advancements related to their lead investigational therapy, SER-155. The therapy showed a 77% relative risk reduction in bacterial bloodstream infections in a Phase Ib study and is progressing to a Phase II study. This study, which targets adults undergoing allo-HSCT, has received Breakthrough Therapy designation from the FDA. Seres anticipates obtaining meaningful clinical results from an interim analysis within 12 months of study initiation, contingent upon funding. The company reported a net income of $8.2 million for Q3 2025, compared to a net loss of $51 million in the same quarter of 2024, due in part to a $25 million installment payment from Nestlé. Their cash position as of September 30, 2025, stood at $47.6 million, expected to fund operations through Q2 2026. Additionally, Seres received a $3.6 million non-dilutive grant from CARB-X for developing a liquid formulation of SER-155, with plans to expand its use in other medically vulnerable populations.Seres Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
35
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.88M | 789.00K | 0.00 | 0.00 | 0.00 | 144.93M |
| Gross Profit | 1.55M | -3.34M | -3.53M | -19.34M | 0.00 | 144.93M |
| EBITDA | -44.34M | 9.83M | -120.30M | -181.42M | -170.93M | -56.72M |
| Net Income | -22.46M | 5.70M | -146.57M | -113.72M | -250.16M | -65.58M |
Balance Sheet | ||||||
| Total Assets | 101.59M | 138.19M | 139.81M | 358.60M | 348.78M | 354.86M |
| Cash, Cash Equivalents and Short-Term Investments | 15.59M | 45.77M | 30.79M | 127.97M | 181.34M | 290.71M |
| Total Debt | 56.64M | 82.97M | 91.64M | 198.78M | 162.59M | 49.21M |
| Total Liabilities | 67.05M | 93.97M | 126.03M | 403.46M | 338.00M | 223.35M |
| Stockholders Equity | 34.53M | 44.22M | 13.78M | -44.86M | 10.78M | 131.51M |
Cash Flow | ||||||
| Free Cash Flow | -51.30M | 865.00K | -148.99M | -125.33M | -238.64M | -2.88M |
| Operating Cash Flow | -51.26M | 1.12M | -148.61M | -117.35M | -228.82M | 6.69M |
| Investing Cash Flow | 187.00K | -42.00K | 142.29M | 10.58M | 82.43M | 64.09M |
| Financing Cash Flow | 14.86M | 13.90M | -90.37M | 71.70M | 129.60M | 1.18M |
Seres Therapeutics Technical Analysis
Negative
4.96
Price Trends
5.92
Negative
7.02
Negative
10.56
Negative
Market Momentum
-0.39
Negative
35.69
Neutral
7.54
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MCRB, the sentiment is Negative. The current price of 4.96 is above the 20-day moving average (MA) of 4.90, below the 50-day MA of 5.92, and below the 200-day MA of 10.56, indicating a bearish trend. The MACD of -0.39 indicates Negative momentum. The RSI at 35.69 is Neutral, neither overbought nor oversold. The STOCH value of 7.54 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MCRB.
Seres Therapeutics Risk Analysis
Seres Therapeutics disclosed 67 risk factors in its most recent earnings report. Seres Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Seres Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $108.19M | -10.66 | -65.73% | ― | ― | 19.64% | |
49 Neutral | $341.38M | -2.44 | -314.08% | ― | 40.21% | 13.40% | |
48 Neutral | $96.04M | -5.26 | -50.17% | ― | ― | 70.27% | |
45 Neutral | $45.13M | -1.88 | -60.32% | ― | ― | 71.26% | |
42 Neutral | $281.62M | -0.58 | 187.62% | ― | -8.79% | -195.46% |
* Healthcare Sector Average
MCRB
Seres Therapeutics
4.54
-13.15
-74.34%
ANIX
Anixa Biosciences
3.18
0.20
6.71%
SRZN
Surrozen
23.96
12.92
117.03%
CGTX
Cognition Therapeutics
1.01
-0.48
-32.21%
IMMX
Immix Biopharma
10.97
8.67
376.96%
CAMP
CAMP4 Therapeutics Corporation
5.44
3.58
192.47%
Seres Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and FinancingRegulatory Filings and Compliance
Seres Therapeutics Streamlines Cambridge Operations with Lease Changes
Positive
Aug 4, 2026
On July 31, 2026, Seres Therapeutics, Inc. executed a Third Amendment to Lease and Termination Agreement with BMR-Sidney Research Campus LLC to end one of its Cambridge facility leases early, aimed at lowering ongoing annual facilities expenses an...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Seres Therapeutics Shareholders Approve Directors and Executive Pay
Positive
Jul 8, 2026
On July 8, 2026, Seres Therapeutics, Inc. held its Annual Meeting of Stockholders, with 4,985,176 shares represented in person or by proxy, amounting to approximately 51.75% of outstanding common stock as of the April 13, 2026 record date. Shareho...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related Announcements
Seres Therapeutics reports positive SER-155 trial results
Positive
Jul 8, 2026
On July 8, 2026, Seres Therapeutics reported encouraging top-line data from a Memorial Sloan Kettering investigator-sponsored trial of SER-155 in 15 patients with moderate-to-severe immune checkpoint inhibitor-related enterocolitis, a common adver...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Seres Therapeutics Reshapes Finances with Lease Restructuring
Positive
Jun 5, 2026
On June 2, 2026, Seres Therapeutics amended its asset purchase agreement with Nestlé’s Société des Produits Nestlé S.A., canceling potential future VOWST sales-based milestone payments of up to $275 million in exchange fo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.